Keratoacanthoma
☆ A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine.
Na al'ada Keratoacanthoma
References
Keratoacanthoma (KA) ciwon fata ne akai-akai wanda aka sani da saurin girma da kuma yuwuwar komawa da kansa. Yawanci yana faruwa a cikin tsofaffi, maza masu launin fata masu tarihin lalacewar rana. Yayin cirewar tiyata ta amfani da cirewa ko tiyatar micrographic Mohs shine jiyya na yau da kullun, akwai wasu zaɓuɓɓukan magani daban-daban da ake da su.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) ciwon daji ne mara nauyi wanda ke farawa daga wasu gland a cikin fata kuma yayi kama da squamous cell carcinoma (SCC) a karkashin na'urar hangen nesa. Akwai muhawara mai gudana game da ko ya kamata a rarraba KA azaman nau'i na SCC mai cin zarafi.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) shine nau'in ciwon daji na biyu da aka fi sani da mutane, musamman a tsakanin tsofaffi. Ana amfani da tiyata yawanci don magance cSCC, amma ga wasu marasa lafiya waɗanda ba za su iya yin tiyata ba ko zaɓi ba, za a iya la'akari da wasu zaɓuɓɓuka kamar jiyya na ciki. An yi amfani da magungunan intralesional na al'ada (methotrexate or 5-fluorouracil) , amma akwai ci gaba da bincike kan sababbin hanyoyin kamar intralesional immunotherapy da oncolytic virotherapy. Anan, za mu kalli jiyya daban-daban na intralesional don cSCC, kama daga hanyoyin gargajiya zuwa dabarun yankan-baki.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Karkashin na'urar hangen nesa, keratoacanthoma yayi kama da carcinoma cell squamous. Yayin da wasu masu ilimin cututtuka suka rarraba keratoacanthoma a matsayin wani abu dabam kuma ba mummunan ba, game da 6% na asibiti da kuma histological keratoacanthoma suna ci gaba zuwa ciwon daji na squamous cell.
○ Diagnosis da Magani
#Dermoscopy
#Skin biopsy